Indication

Conditioning prior to allogeneic hematopoietic stem cell transplant

Conditioning prior to allogeneic hematopoietic stem cell transplant refers to a procedural preparatory state rather than an intrinsic disease entity. Read more about Conditioning prior to allogeneic hematopoietic stem cell transplant

32 drugs 29 manufacturers

Advertisement

Drugs that treat it

Common Conditioning prior to allogeneic hematopoietic stem cell transplant therapies.

Showing 19–27 of 32 drugs

BUSULFAN

ALKYL SULFONATES·CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
ACCORD HEALTHCA

BUSULFAN

CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
APOTEX CORP

BUSULFAN

ALKYL SULFONATES·CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
ARMAS PHARMACEU

MYLERAN (busulfan)

CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT·+1
WOODWARD PHARMA

MYLERAN (busulfan)

ALKYL SULFONATES·CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT·+1
WAYLIS THERAPEU

THIOTEPA

ALKYLATING AGENTS·CARCINOMA OF BREAST·+6
STI PHARMA, LLC

GRAFAPEX (treosulfan)

ALKYL SULFONATES·CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
MEDAC PHARMA, I

BUSULFAN

ALKYL SULFONATES·CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
MEITHEAL PHARMA

THIOTEPA

ALKYLATING AGENTS·CARCINOMA OF BREAST·+6
MEITHEAL PHARMA
Filter & compare in the drug finder →Opens the drug finder with Conditioning prior to allogeneic hematopoietic stem cell transplant preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Conditioning prior to allogeneic hematopoietic stem cell transplant.

Conditioning prior to allogeneic hematopoietic stem cell transplant refers to a procedural preparatory state rather than an intrinsic disease entity.

Administered to pediatric or adult patients with hematologic malignancies, marrow failure syndromes, or congenital immunodeficiencies, this clinical state involves intensive pre-transplant cytoreduction and immunosuppression.

Pathophysiologically, the regimen—delivered via myeloablative, reduced-intensity, or non-myeloablative intensities—targets the host hematopoietic and immune systems through profound myelodepletion and lymphodepletion.

This eliminates residual diseased cells, empties marrow stem cell niches, and suppresses recipient immune responses to prevent graft rejection and permit successful donor cell engraftment.

Personalize your experience

Follow Conditioning prior to allogeneic hematopoietic stem cell transplant and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it